Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| HER2 Higher in gallbladder/extrahepatic | 10-20% | IHC 3+ or amplification | Wikipedia |
| IDH1 / IDH2 | 10-20% | IDH1 mutation (intrahepatic) | cBioPortal (TCGA) |
| FGFR2 | 10-15% | Fusion (intrahepatic) | cBioPortal (TCGA) |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
4 cell lines, 1 mouse models and 6 repositories are listed for this cancer. See them →